Can I read Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer on EtoBox?

Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer by Iwase, Madoka; Ando, Masashi; Aogi, Kenjiro; Aruga, Tomoyuki; Inoue, Kenichiro; Shimomura, Akihiko; Tokunaga, Eriko; Masuda, Norikazu; Yamauchi, Hideko; Yamashita, Toshinari; Iwata, Hiroji is a Medicine article available to read on EtoBox.

What is Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer about?

## Purpose: Addition of carboplatin (cbdca) to neoadjuvant chemotherapy (nac) in triple-negative breast cancer (tnbc) has improved pathological complete response (pcr) rates in previous studies. we present long-term survival outcomes (disease-free survival [dfs], pre-planned secondary endpoint; overall survival [os], post hoc exploratory endpoint) of our randomized study of the addition of cbdca to nac for her2-negative breast cancer. ## Methods: Patients with stage ii/iii, her2-negative breast cancer (n = 179) were randomly assigned to receive cp-cef (four 3-week cycles of cbdca [area under the curve, 5 mg/ml/min, day 1] and weekly paclitaxel [wptx, 80 mg/m, day 1, 8, 15] followed by four 3-week cycles of cyclophosphamide, epirubicin, and 5-fluorouracil [cef, 500/100/500 mg/m]) or p-cef (four cycles of wptx followed by four cycles of cef) as nac. dfs and os were analyzed at each population of pcr status and assigned treatment arm. ## Results: Of 179 patients, 154 were available for long-term follow-up. at a median follow-up of 6.6 years (range, 0.7-8.0 years), patients who achieved pcr [n = 42, 23.5% (cp-cef: n = 28, p-cef: n = 16)] had longer dfs and os than non-pcr patients [dfs

Who reads Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer?

Author

Iwase, Madoka; Ando, Masashi; Aogi, Kenjiro; Aruga, Tomoyuki; Inoue, Kenichiro; Shimomura, Akihiko; Tokunaga, Eriko; Masuda, Norikazu; Yamauchi, Hideko; Yamashita, Toshinari; Iwata, Hiroji

Publisher

Springer US; Springer-Verlag; Kluwer Academic Publishers; Springer Science and Business Media LLC (ISSN 0167-6806)

Published

2020

Language

EN

Field

Medicine (Health Sciences)